consistent with COVID-19. The LumiraDx SARS-CoV-2 Ag Test is intended for use by medical professionals or operators who are proficient in performing tests in point of care settings.
The same trend was observed in our analysis of the single SARS-CoV-2 antigen test introduced thus far with EUA status. Tests with such performance characteristics will identify individuals with the highest viral burden. However, such a high detection threshold will be unlikely to fully meet public or individual health goals in the COVID-19 You are being given this Fact Sheet because your sample(s) was tested for the Coronavirus Disease 2019 (COVID-19) using the LumiraDx SARS-CoV-2 Ag Test. This Fact Sheet contains information to help you understand the risks and benefits of using this test for the diagnosis of COVID-19. After reading this Fact Sheet, if you have questions orHumasis COVID-19 Ag Test uses monoclonal antibodies specific to COVID-19 antigens to detect COVID-19 specific antigens in human nasal swab and nasopharyngeal swab specimens. The test shows the same sensitivity and specificity for OMICRON and other virus variants.ZSTMY.